Skip to content

Advances in colon-targeted nano-drug delivery systems: challenges and solutions

Document Type
Publications · Review Article
Registered DB
KCISCIEScopus
Journal Ranking
JCR Q2Scopus Q1
Journal
Archives of Pharmacal Research43(1) · pp.153 · 2020
Citation
Web of Science 201Scopus 243KCI 2
FWCI (Scopus)
0
JCR IF
JCR 2019 2.934
ISSN
0253-6269

Authors

  1. Naeem, MuhammadFirst authorCollege of Pharmacy, Pusan National University, Busan, South Korea
  2. Awan, Uzma AzeemDepartment of Biological Sciences, National University of Medical Sciences, Rawalpindi, Punjab, Pakistan
  3. Subhan, FazliDepartment of Biological Sciences, National University of Medical Sciences, Rawalpindi, Punjab, Pakistan
  4. caojiafuCollege of Pharmacy, Pusan National University, Busan, South Korea
  5. SHWE PHYU HLAINGCollege of Pharmacy, Pusan National University, Busan, South Korea
  6. Lee, JuhoCollege of Pharmacy, Pusan National University, Busan, South Korea
  7. Im, EunokCollege of Pharmacy, Pusan National University, Busan, South Korea
  8. Jung, YunjinCollege of Pharmacy, Pusan National University, Busan, South Korea
  9. Yoo, JinwookCorresponding authorCollege of Pharmacy, Pusan National University, Busan, South Korea

Abstract

Nano-drug delivery systems (NDDS) for colon-targeted drug delivery are an active area of research on local diseases affecting the colon, such as ulcerative colitis, Crohn's disease, colon cancer, and for the delivery of peptide or protein drugs and vaccinations. In particular, targeted nano-drug delivery to the colon is advantageous for colon-specific diseases because nanoparticles can accumulate in diseased parts, improve the efficacies of therapeutics, and enable localized treatments, which reduces systemic toxicity. However, there are many hurdles, such as burst drug release, enzyme and acidic degradation of drug and carrier in the stomach, pH variations, mucus entrapment, and systemic uptake in the upper small intestine, which could challenge and compromise the successful delivery of NDDS to the colon. With advancements in NDDS, it may be possible to overcome these challenges leading to efficient drug delivery for colon-specific disorders. This review describes a few of the potential colon-specific drug delivery areas and the challenges faced by colon-targeted orally administered delivery systems, and provides an updated summary of recent advances in the development of orally administered NDDS for colon targeting, and the future advances in this research.

Keywords

Nano-drug deliveryColon-targetingColorectal cancerUlcerative colitisINFLAMMATORY-BOWEL-DISEASESOLID-LIPID NANOPARTICLESPH-SENSITIVE NANOPARTICLESN-TRIMETHYL CHITOSANIN-VIVOULCERATIVE-COLITISPOLYMERIC NANOPARTICLESORAL DELIVERYINTESTINAL INFLAMMATIONLIPOSOMAL FORMULATIONS

Identifiers

Scopus EID
2-s2.0-85078432346
WoS UID
000515620600005
KCI
ART002556372